Details for Patent: 6,670,351
✉ Email this page to a colleague
Title: | Method for ameliorating muscle weakness/wasting in a patient infected with human immunodeficiency virus-type 1 |
Abstract: | A method for attenuating the HIV-associated myopathy and muscle wasting associated with infection by human immunodeficiency virus-Type 1. Administration of oxandrolone in a daily dosage of about 2.5 to about 20 milligrams is described. |
Inventor(s): | Berger; Joseph R. (Miami, FL) |
Assignee: | Bio-Technology General Corporation (Iselin, NJ) |
Filing Date: | Dec 22, 1999 |
Application Number: | 09/469,817 |
Claims: | 1. A method for ameliorating HIV-associated myopathy and muscle wasting in an AIDS patient which comprises administering a therapeutically effective amount of oxandrolone to the AIDS patient. 2. The method in accordance with claim 1 wherein the therapeutically effective amount comprises a daily dosage of between about 2.5 to about 30 milligrams. 3. The method in accordance with claim 1 wherein the therapeutically effective amount comprises a daily dosage of between about 2.5 to about 20 milligrams. 4. The method in accordance with claim 3 wherein the daily dosage is about 20 milligrams. 5. The method in accordance with claim 3 wherein the daily dosage is about 15 milligrams. 6. The method in accordance with claim 1 wherein the oxandrolone is administered orally. 7. The method in accordance with claim 6 wherein the oxandrolone is administered in the form of a tablet. 8. The method in accordance with claim 2 wherein the oxandrolone is administered orally. 9. The method in accordance with claim 8 wherein the oxandrolone is administered in the form of a tablet. 10. The method in accordance with claim 3 wherein the oxandrolone is administered orally. 11. The method in accordance with claim 10 wherein the oxandrolone is administered in the form of a tablet. 12. The method in accordance with claim 4 wherein the oxandrolone is administered orally. 13. The method in accordance with claim 12 wherein the oxandrolone is administered in the form of a tablet. 14. The method in accordance with claim 5 wherein the oxandrolone is administered orally. 15. The method in accordance with claim 14 wherein the oxandrolone is administered in the form of a tablet. 16. The method in accordance with claim 1 wherein the oxandrolone is administered daily for a time period in the range of about two weeks to about six months. 17. The method in accordance with claim 6 wherein the oxandrolone is administered daily for a time period in the range of about two weeks to about six months. 18. The method in accordance with claim 8 wherein the oxandrolone is administered daily for a time period in the range of about two weeks to about six months. 19. The method in accordance with claim 10 wherein the oxandrolone is administered daily for a time period in the range of about two weeks to about six months. 20. The method in accordance with claim 12 wherein the oxandrolone is administered daily for a time period in the range of about two weeks to about six months. 21. The method in accordance with claim 14 wherein the oxandrolone is administered daily for a time period in the range of about two weeks to about six months. 22. The method in accordance with claim 1 wherein the oxandrolone is administered percutaneously. 23. The method in accordance with claim 1 wherein the oxandrolone is administered intravenously. 24. The method in accordance with claim 1 wherein the oxandrolone is administered intramuscularly. 25. The method in accordance with claim 1 wherein the oxandrolone is administered sublingually. 26. The method in accordance with claim 1 wherein the oxandrolone is administered transdermally. 27. The method in accordance with claim 1 wherein the oxandrolone is administered in a unit dose of about 2 to about 5 milligrams three times daily. 28. The method in accordance with claim 2 wherein the oxandrolone is administered in a unit dose of about 2 to about 5 milligrams three times daily. 29. The method in accordance with claim 3 wherein the oxandrolone is administered in a unit dose of about 2 to about 5 milligrams three times daily. 30. The method in accordance with claim 4 wherein the oxandrolone is administered in a unit dose of about 2 to about 5 milligrams three times daily. 31. The method in accordance with claim 5 wherein the oxandrolone is administered in a unit dose of about 2 to about 5 milligrams three times daily. 32. The method in accordance with claim 1 wherein the oxandrolone is administered in a unit dose of about 1 to about 5 milligrams three or four times daily. 33. The method in accordance with claim 2 wherein the oxandrolone is administered in a unit dose of about 1 to about 5 milligrams three or four times daily. 34. The method in accordance with claim 3 wherein the oxandrolone is administered in a unit dose of about 1 to about 5 milligrams three or four times daily. 35. The method in accordance with claim 4 wherein the oxandrolone is administered in a unit dose of about 1 to about 5 milligrams three or four times daily. 36. The method in accordance with claim 5 wherein the oxandrolone is administered in a unit dose of about 1 to about 5 milligrams three or four times daily. |